BACKGROUND: Women veterans have high rates of medical comorbidities and may be particularly vulnerable to adverse health outcomes associated with unintended pregnancy. OBJECTIVES: The objective of the study was to estimate the prevalence of medical contraindications to estrogen-containing combined hormonal contraception among women veterans of reproductive age and to evaluate the relationship between contraindications and contraceptive use. STUDY DESIGN: This was a secondary analysis of data from a crosssectional, telephone-based survey with a national sample of 2302 female veterans, aged 18e45 years, who use the Veterans Administration Healthcare System for primary care. This analysis included women at risk of unintended pregnancy, defined as heterosexually active and not pregnant or trying to conceive and with no history of hysterectomy or infertility. Seven contraindications to combined hormonal contraception were identified using survey data or medical diagnosis codes: hypertension; coronary artery disease; active migraine in women older than 35 years or migraine with aura; smoking in women older than 35 years; and a history of thromboembolism, stroke, or breast cancer. Outcomes were current use of combined hormonal contraception and contraceptive method type (combined hormonal contraception, and other prescription methods, nonprescription methods or no method). Multivariable logistic and multinomial regression were used to assess the relationship between
T he Veterans Affairs (VA) Healthcare System is the largest integrated health care system in the United States. Over the past several decades, the number of women veterans using VA for health care has grown dramatically, and the majority of new female enrollees are of reproductive age. 1, 2 However, until recently, little has been known about contraceptive use and unintended pregnancy among women veterans.
Because women veterans have high rates of medical and psychiatric comorbidities compared with women in the general population, 1, 3 this population may be at increased risk of the negative health outcomes associated with unintended pregnancy, including inadequate prenatal care, substance use during pregnancy, preterm birth, and low birthweight. 4 Ensuring access to contraceptive methods and counseling is therefore critical to support the reproductive and overall health of women veterans.
To address the needs of this growing population, VA policy requires that women veterans have access to comprehensive primary care from a provider who is proficient in gender-specific care, including contraceptive counseling and management. 1, 5 VA pharmacies provide the full range of hormonal contraceptive methods, 6 and referrals to a gynecologist (on site, at another VA site, or at a non-VA site via contract care) can be made as needed for contraceptive procedures such as sterilization or placement of intrauterine devices (IUDs) or subdermal implants. 1, 7 Nevertheless, variability exists across VA sites regarding expertise and comfort level of women's health providers and consequent availability of on-site or same-day provision of procedural methods. 8, 9 Among contraceptive methods, estrogen-containing combined hormonal contraception (CHC), including most formulations of the birth control pill, the transdermal patch, and the vaginal ring, remain the most popular forms of birth control; greater than 80% of sexually active women in the United States have ever used the birth control pill. 10 Although most women can safely use CHC, specific medical conditions serve as relative or absolute contraindications, primarily because of concerns for increased risk of thrombotic and cardiovascular conditions with estrogen use. 11 The US Medical Eligibility Criteria for Contraceptive Use (US MEC), produced by the Centers for Disease Control and Prevention, provides evidence-based recommendations regarding the safety of contraceptive methods for women with various medical conditions. 12, 13 Despite the specificity of these guidelines, the prevalence of medical contraindications to CHC is poorly defined. Prior studies estimate that anywhere from 2% to 39% of reproductive-aged women are medically ineligible to use estrogen-containing methods. [14] [15] [16] [17] Medical contraindications to CHC may have an impact on the eligibility for and use of effective contraceptive methods, which may in turn contribute to unintended pregnancy. Understanding the impact of contraindications to CHC on contraceptive use among women veterans is important to meet the VA's goal of providing high-quality reproductive health care, particularly given the high burden of medical comorbidities among the growing number of women using the VA.
Using data from a nationally representative, cross-sectional survey of female VA users, we aimed to estimate the prevalence of contraindications to CHC in a population of women veterans at risk of unintended pregnancy. We then aimed to characterize the relationship between contraindications and contraceptive use.
Materials and Methods

Study design and population
This is a secondary analysis of data from the Examining Contraceptive Use and Unmet Need Among Women Veterans (ECUUN) study. 18 The ECUUN study included a cross-sectional, telephonebased survey of a random, nationally representative sample of 2302 women veterans who use the VA for health care. Eligible participants were female veterans aged 18e45 years who had at least 1 primary care visit within the VA Healthcare System in the prior 12 months. Potential participants were identified using VA administrative data, yielding a sampling frame of approximately 130,000 women. Overall, 8198 potential participants were randomly selected and mailed study invitations; 2769 participants were screened and enrolled in the study and 2302 completed the survey, for an overall response rate of 28%.
The survey completion rate was 83% among enrolled participants. Using VA administrative data, ECUUN participants were compared with nonparticipants and found to be similar with regard to age, race/ethnicity, marital status, income, geographic region, and the presence of medical and mental illness. 18 This suggests that the ECUUN sample is representative of reproductiveaged female VA users at large.
Participants completed computerassisted telephone interviews between April 2014 and January 2016. All participants provided informed consent. This study was approved by the Institutional Review Boards of the University of Pittsburgh and the VA Pittsburgh Healthcare System. Complete methodology has been previously reported. 18 This analysis was limited to women identified as at risk of unintended pregnancy, defined as sexually active with a male partner within 3 months prior to the study interview, not currently pregnant, trying to conceive, or less than 2 months postpartum and without a history of hysterectomy or other infertility. Among the 2302 women veterans in the ECUUN sample, 1173 (51%) were identified as being at risk of unintended pregnancy. Four women in the at-risk cohort reported current use of contraception but did not specify a method type and were therefore excluded from analysis, resulting in a study sample of 1169 women.
Measures
The primary predictor variable was at least 1 medical contraindication to CHC use. For every category of contraceptive methods, including CHC, the US MEC characterizes specific medical conditions as category 1 (no restriction on use), category 2 (advantages generally outweigh theoretical or proven risks), category 3 (theoretical or proven risks usually outweigh advantages), or category 4 (unacceptable health risk). 13 We defined contraindications to CHC as the presence of at least 1 of the following category 3 or category 4 conditions: hypertension, coronary artery disease, history of thromboembolism, history of stroke, history of breast cancer, migraine with aura, migraine without aura in women older than age 35 years, and current smoking by women older than age 35 years.
Contraindications were primarily identified via self-report on the ECUUN survey. Participants were asked whether they had ever (in their lifetime) been diagnosed with or received treatment for the above-mentioned conditions, and smoking was assessed by asking, "Do you currently smoke or use tobacco?" Self-report was believed to be the most accurate means of assessing contraindications because of recognized inconsistencies in medical diagnosis coding within the VA health care system; medical diagnosis codes are known to underestimate the true prevalence of medical conditions in the VA because they are not used for physician billing as in other health care systems and because administrative data may exclude acute events and diagnoses occurring prior to VA enrollment or in non-VA settings. 1, 19 Furthermore, prior research in non-VA settings suggests that self-report is adequately reliable to assess medical contraindications to CHC 17, 20, 21 ; in veteran populations, self-report is reliable for assessing similar, chronic health conditions. 19, 22 Because the survey instrument was not sufficiently detailed to distinguish between category 3 and category 4 contraindications (eg, controlled vs uncontrolled hypertension, cigarettes smoked per day), only conditions definitively representing at least a category 3 contraindication were included in this analysis. While category 3 conditions do not represent absolute contraindications, there is broad consensus around the guideline that women with these conditions generally should not use CHC.
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The most recent update to the US MEC, published in July 2016, describes migraine with aura as a category 4 contraindication and recharacterizes migraine in women older than age 35 years from a category 3 to a category 2 condition. 13 Because this update was The survey instrument assessed for lifetime incidence of migraines but not for active migraine or the presence of aura symptoms. Therefore, diagnosis of migraine with aura was determined by the presence of migraine with aura International Classification of Diseases, ninth revision, Clinical Modification diagnosis codes (346.0, 346.3, 346.5, 346.6) in VA administrative data in the 10 year period preceding the participants' study interview. Active migraine in women older than age 35 years was defined by the presence of diagnosis codes for any migraine (346.xx) over the 12 months prior to the study interview for participants 35 years of age or older at interview.
Outcomes of interest were current use of CHC and current contraceptive method type, including no method. Current contraceptive use was defined as self-reported use of a method during the month preceding the study interview, as per convention.
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Contraceptive methods were classified as follows: CHC (pill, patch, ring); non-CHC prescription methods (IUD, subdermal implant, medroxyprogesterone injection, male and female sterilization); nonprescription methods (barrier methods, fertilityawareness methods, withdrawal); or no method.
Women reporting the current use of more than 1 method were classified first by any use of a CHC method and then according to their most effective method type. 25 For example, a woman reporting use of the pill and a partner's vasectomy would be classified as using a CHC method, and a woman reporting the use of an IUD and condoms would be classified as using a non-CHC prescription method.
The survey instrument did not distinguish between the use of combined hormonal and progestin-only pills; thus, some women who reported current use of the birth control pill may have been incorrectly characterized as using CHC. However, the use of progestin-only pills is low in the United States overall, 26 and VA pharmacy data for ECUUN participants at risk of unintended pregnancy indicates that only 5% of women with VA prescriptions for oral contraception in the month prior to their study interview were prescribed progestin-only pills.
The following patient-and facilitylevel covariates were assessed using survey data: age, race/ethnicity, marital status, education, income, insurance, parity, history of military sexual trauma, sex of the VA primary care provider (PCP), whether a woman receives care at a VA women's health clinic, and whether a woman sees their VA PCP for almost all care and/or for routine gynecological care such as Papanicolaou smears. VA administrative data were used to assess other facility-level characteristics, including geographic region.
Statistical analysis
Descriptive statistics were generated to describe study population characteristics for the total sample and by the presence of medical contraindications to CHC. The frequency of any contraindications to CHC and each individual condition was calculated as well as rates of contraceptive method type, including no method, by contraindication status. c 2 tests were used to test differences in rates of contraceptive method type by the presence of contraindications to CHC.
Logistic regression was used to assess the relationship between contraindications to CHC and CHC use. Multinomial logistic regression was used to assess the relationship between contraindications to CHC and contraceptive method type, including no method, using CHC as the reference group. Interactions between race/ethnicity and contraindication status were assessed and included in the final model if significant.
Patient-, provider-and facility-level covariates that were potentially associated with contraindications to CHC in bivariate analyses at the P < .10 level were included in the model. All analyses were conducted in Stata 14 (StataCorp.
College Station, TX), with statistical significance set at P < .05.
Results
In our sample of 1169 women veterans identified as at risk of unintended pregnancy, the mean age was 33.9 years (range, 21e45 years); 54.2% were nonHispanic white, 25.7% non-Hispanic black, 12.7% Hispanic or Latina, and 7.4% non-Hispanic other, including multiracial, Asian, Pacific Islander, and Native American women ( Table 1 ). The majority of women were married or cohabitating (58.6%) and had a bachelor's degree or higher (52.0%).
Overall, 339 women (29.0%) had at least 1 medical contraindication to CHC use ( Table 2) . Hypertension was the most prevalent condition (14.9%), followed by migraine with aura or migraine older than age 35 years (8.7%), and current smoking by women older than age 35 years (7.4%). Among women 35 years old or older, 16.5% were current smokers, compared with 18.1% of women in the total sample. Most women with contraindications to CHC had only 1 condition (n ¼ 275, 81.1%); 54 women (15.9%) had 2 contraindications and 10 women (3.0%) had 3 contraindications (Appendix). Women with contraindications to CHC were generally older, had higher parity, and were more likely to be non-Hispanic black than women without contraindications (Table 1) .
Current contraceptive use and method type varied among women veterans with and without contraindications to CHC. Overall, 88.5% of all women veterans at risk of unintended pregnancy reported the use of a contraceptive method in the past month: 22.1% used CHC methods, 50.5% used non-CHC prescription methods, and 15.9% used nonprescription methods ( Table 2) .
Rates of CHC use were lower among women with contraindications compared with noncontraindicated women (13.6% vs 25.5%, P < .001). Among the 258 women using CHC, 46 (17.8%) had contraindications to estrogen use; 25 women had hypertension, 14 had migraine, and 11 were current smokers older than age 35 years.
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Compared with women without contraindications, women with contraindications had higher rates of use of non-CHC prescription methods (56.1% vs 48.2%, P ¼ .02) and higher rates of contraceptive nonuse (14.8% vs 10.2%, P ¼ .03). No significant differences were seen for the use of nonprescription methods in the bivariate analysis. ajog.org
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A more detailed breakdown of the percentage of women using individual contraceptive methods by contraindication status is shown in the Figure. The pill, which comprised the majority of CHC use, was used by a smaller proportion of women with contraindications compared with women without contraindications (11.2% vs 20.1%, P <.001). Women with contraindications had higher rates of tubal sterilization compared with women without contraindications (22.4% vs 13.3%, P < .001), while rates of use for other non-CHC prescription methods (vasectomy, IUD, implant, and injection) were not significantly different.
In unadjusted logistic regression analyses, women with contraindications to CHC were less likely to report the use of CHC methods in the past month compared with women without contraindications (odds ratio [OR], 0.46; 95% confidence interval [CI], 0.32e0.65) ( Table 3 ). The association between contraindications and CHC use remained significant after controlling for age, race/ ethnicity, marital status, education, parity, insurance status, and VA PCP sex (adjusted OR, 0.54; 95% CI, 0.37e0.79). There were no interactions between Original Research GYNECOLOGY ajog.org race/ethnicity and contraindication status.
In both unadjusted and adjusted multinomial logistic regression analyses, women with contraindications to CHC were significantly more likely than women without contraindications to use non-CHC prescription methods (adjusted OR, 1.74; 95% CI, 1.17e2.60), nonprescription methods (adjusted OR, 1.96; 95% CI, 1.19e3.22) , and no method (adjusted OR, 2.29; 95% CI, 1.35e3.89) as compared with using CHC (Table 3) .
Comment
In a nationally representative sample of female VA users at risk of unintended pregnancy, greater than one quarter of women had at least 1 specific medical contraindication to combined hormonal contraception. Women veterans with contraindications were appropriately less likely to use CHC methods compared with women without contraindications and were more likely to use other methods such as sterilization and nonprescription methods, relative to CHC. However, women with contraindications were also significantly more likely to report nonuse of any contraception. Thus, while our findings indicate some degree of appropriate medical screening for CHC method use, they also suggest an unmet need for contraception among a population of medically vulnerable and sexually active women not desiring pregnancy.
That 29% of the women in our study had at least 1 medical contraindication to CHC is consistent with the reported high rates of medical comorbidities among woman veterans overall 1 but is greater than most estimates of the prevalence of estrogen contraindications among women of reproductive age. Estimates of medical contraindications to CHC in the literature range from 2% among 14-45 year old women seeking hormonal contraception 14 to 13% among privately insured 18-40 year old women in Pennsylvania 15 to 16% among a national sample of fecund women aged 20e50 years. 16 One study found a contraindication rate of 39% among primarily Latina women in El Paso, TX 17 ; however, this was an older population with high rates of undiagnosed hypertension. Our results suggest that women veterans of reproductive age have a relatively high burden of medical contraindications to estrogen use compared with estimates in other US populations.
Our finding that women with medical contraindications to estrogen had significantly lower rates of CHC use compared with women without contraindications is consistent with some prior reports 16 but contrasts with a recent study that found that rates of CHC use did not vary significantly between women with and without contraindications.
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Among all current users of CHC in our study population, 17.8% had at least 1 contraindication to CHC use, a rate comparable with prior estimates of inappropriate CHC use.
15, 16, 27, 28 Women with contraindications to estrogen may have an increased risk of venous thromboembolism, cardiovascular events, and ischemic stroke with the use of CHC; however, the use of CHC by these women may still be less dangerous than the thrombotic risks inherent in pregnancy and delivery. 11, 29 Therefore, while the use of CHC by women with contraindications may reflect inappropriate prescribing or failure to adequately screen for conditions precluding the use of these methods, it is also conceivable that some women may have opted for the use of CHC after appropriate counseling, accepting the balance of known risks and benefits of these medications. This possibility is particularly relevant, given that the ECUUN survey instrument was not sufficiently detailed to distinguish between category 3 (relative) and category 4 (absolute) contraindications to CHC use. Nevertheless, clinical guidelines clearly discourage the prescribing of CHC to patients with a recognized category 3 condition.
Decreased CHC use among women with contraindications was partially compensated for by relative increases in other prescription and nonprescription methods, although we also observed an ajog.org GYNECOLOGY Original Research increased nonuse of contraception among these women. While women veterans overall have similar rates of an unmet need for contraception compared with the general US population, 18 the elevated rate of nonuse among women veterans with medical comorbidities may be a cause for concern.
Many women who are ineligible for CHC methods are likely candidates for highly effective, long-acting reversible contraceptive methods (LARC), including IUDs and implants. LARC use has increased more than 5-fold among US women in the past decade, 30 and ECUUN data suggests that female VA users use these methods at higher rates than women in the general US population. 18 In this study, however, higher rates of tubal sterilization, rather than LARC use, appear to drive increases in non-CHC prescription method use among women with contraindications. This finding is likely reflective of the older age and higher parity of women with contraindications but may also reflect this cohort's ineligibility for popular reversible contraceptive options. Despite the growing visibility and popularity of LARC methods, alternatives to wellknown methods such as the pill may not be apparent or acceptable to women who cannot use CHC, thus contributing to contraceptive nonuse or the decision to seek a permanent form of contraception.
The VA has made great strides toward provision of comprehensive, genderspecific care by a single women's health provider 1, 9 ; however, on-site provision of LARC methods varies, and discomfort or lack of LARC placement skills among primary care providers may still present barriers to LARC use among interested patients. 8 Finally, in primary care settings, management of other conditions may take precedence over discussions about contraception, particularly for medically complex patients. Evidence suggesting that women with chronic medical conditions may be less likely to receive contraceptive counseling 31, 32 supports the hypothesis that women veterans with medical comorbidities may receive suboptimal contraceptive care; however, future research is needed in this area.
This study has several limitations. First, the response rate was relatively low, at 28%; however, participants did not differ significantly from nonparticipants in terms of important demographic and clinical characteristics. Furthermore, our results may not be generalizable to women veterans who do not use the VA for health care. Female VA users are of lower average income levels, more likely to be a racial/ethnic minority, and are more likely to carry a medical or psychiatric diagnosis as compared with women veterans who do not use VA. 33 Second, our reliance on self-reported medical conditions may have resulted in inaccurate or incomplete characterization of contraindications to CHC use; however, prior work suggests that selfreport is reliable for the assessment of the conditions considered in this study. 17, [19] [20] [21] [22] Because of inadequate specificity of the survey instrument for migraine conditions, we used International Classification of Diseases, ninth revision, Clinical Modification codes for a history of migraine with aura and active migraine in women older than age 35 years; thus, our estimated prevalence of migraine contraindications (8.7%) is likely conservative. Despite this limitation in our survey design, we included these diagnoses to the best of our ability because of their importance as prevalent and potentially underrecognized contraindications to CHC use, 34 particularly among younger, healthier women.
Finally, it is difficult to directly compare our results with prior literature examining medical contraindications to CHC because studies report on cohorts of varying age ranges and demographic characteristics, and methods used to evaluate medical contraindications are nonstandardized.
Our evaluation of contraindications to CHC and contraceptive use among women veterans provides insight into the state of contraceptive care for female VA users who are medically ineligible for popular and effective hormonal methods. As the US MEC continues to evolve and is increasingly utilized as a guide for safe prescribing of contraceptive methods, increased care should be paid to understanding how contraindications limit women's choices and consequent ability to use effective contraceptive methods and to improve contraceptive options and counseling for these women.
Future research should aim to better understand contraceptive counseling for and decision making among women 
